中國的臨床研究機會和美國食品藥品監督管理局批准的途徑 - 白皮書
Oct 26, 2022 07:00 HKT |  |
|
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
Oct 25, 2022 18:00 HKT | |
|
Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round
Oct 20, 2022 14:45 HKT |  |
|
Sirnaomics将在未来两个行业学术会议上汇报GalAhead(TM)疗法递送平台及相关项目的最新进展
Oct 19, 2022 13:03 HKT | |
|
Sirnaomics將在未來兩個行業學術會議上匯報GalAhead(TM)療法遞送平台及相關項目的最新進展
Oct 19, 2022 13:02 HKT | |
|
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences
Oct 19, 2022 13:01 HKT | |
|
생명공학 분야 웨비나: 시장 동향, 우선 순위, 예측 및 FDA 승인 경로
Oct 19, 2022 06:00 HKT | |
|
아쿠라바이오, 글로벌 성장 프로그램 추진을 위해 유능한 고위 경영진 임명
Oct 19, 2022 06:00 HKT |  |
|
访中国抗体制药创办人梁瑞安：现是香港发展创科最好时候
Oct 18, 2022 13:30 HKT |  |
|
訪中國抗體製藥創辦人梁瑞安：現是香港發展創科最好時候
Oct 18, 2022 13:29 HKT | |
|
AcuraBio Appoints Talented Senior Executives to Drive Global Growth Program
Oct 18, 2022 07:00 HKT | |
|
生物技术领域网络研讨会：市场趋势、优先事项、预测和 FDA 批准途径
Oct 17, 2022 13:00 HKT | |
|
生物技術領域網絡研討會：市場趨勢、優先事項、預測和 FDA 批准途徑
Oct 17, 2022 13:00 HKT | |
|
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
Oct 17, 2022 11:00 HKT | |
|
医思健康料23上半财年销售额创新高至不少于18亿港元 按年升不少于17%
Oct 17, 2022 08:50 HKT |  |
|
醫思健康料23上半財年銷售額創新高至不少於18億港元 按年升不少於17%
Oct 17, 2022 08:49 HKT | |
|
EC Healthcare expects a record-high semi-annual sales volume in first half of FY23 of no less than HK$1.8 billion, Represents no less than 17% Y-o-Y increase
Oct 17, 2022 08:48 HKT | |
|
佈局海外 金活醫藥集團完成收購法國Innopharm公司
Oct 14, 2022 23:07 HKT |  |
|
노보텍 인디아, ‘글로벌 근로 표준 당국’으로부터 “2022년 여성을 위한 최고의 직장”으로 선정
Oct 14, 2022 11:00 HKT | |
|
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech
Oct 13, 2022 22:40 HKT |  |
|